7WKZ
Crystal structure of the HSA complex with mycophenolate and aripiprazole
7WKZ の概要
| エントリーDOI | 10.2210/pdb7wkz/pdb |
| 分子名称 | Serum albumin, 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one, MYCOPHENOLIC ACID (3 entities in total) |
| 機能のキーワード | drug, complex, transport protein |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 134679.88 |
| 構造登録者 | |
| 主引用文献 | Yamasaki, K.,Teshima, H.,Yukizawa, R.,Kuyama, K.,Tsukigawa, K.,Nishi, K.,Otagiri, M.,Kawai, A. Structural Basis of the Change in the Interaction Between Mycophenolic Acid and Subdomain IIA of Human Serum Albumin During Renal Failure. J.Med.Chem., 66:951-961, 2023 Cited by PubMed Abstract: Mycophenolic acid (MP) is an active metabolite of mycophenolate mofetil, a widely used immunosuppressive drug. MP normally exhibits high plasma protein binding (97-99%), but its binding rate is decreased in patients with renal insufficiency. This decreased protein binding is thought to be associated with leukopenia, a side effect of MP. In this study, we characterized the change in protein binding of MP in renal failure patients. Our findings indicate that MP binds strongly to subdomain IIA of human serum albumin. X-ray crystallographic data indicated that the isobenzofuran group of MP forms a stacking interaction with Trp214, and the carboxyl group of MP is located at a position that allows the formation of hydrogen bonds with Tyr150, His242, or Arg257. Due to the specific binding of MP to subdomain IIA, MP is thought to be displaced by uremic toxin (3-carboxy-4-methyl-5-propyl-2-furan-propionic acid) and fatty acids (oleate or myristate) that can bind to subdomain IIA, resulting in the decreased plasma protein binding of MP in renal failure. PubMed: 36538495DOI: 10.1021/acs.jmedchem.2c01790 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.992 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






